Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Stage IV Non-small Cell Lung Cancer
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in patients with stage IV non-squamous…
- Trial name
- NCT03559049
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
This phase Ib/II trial studies the best dose of carboplatin when given together with berzosertib, gemcitabine and pembrolizumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung…
- Trial name
- NCT04216316
- Testing
- Berzosertib, Biospecimen Collection, Carboplatin
- Where
- 34 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial compares how well sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan in combination with ivonescimab works in treating patients with non-small cell lung cancer…
- Trial name
- NCT07393555
- Testing
- Biospecimen Collection, Computed Tomography, Ivonescimab
- Where
- 41 sites in United States
- Volunteers
- 117 people
- Sponsor
- SWOG Cancer Research Network
Melanoma (Skin Cancer), Non Small Cell Lung Cancer
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
The trial will test if the combination of bexmarilimab and nivolumab can help patients whose cancers have stopped responding to immunotherapy treatment. It will focus on two cancers: non-small cell lung cancer and melanoma.
- Conditions
- Melanoma (Skin Cancer), Non Small Cell Lung Cancer, Solid Tumor in Advanced Stage
- Trial name
- BLAZE (NCT07718243)
- Testing
- Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 62 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Carcinoma, Non-Small-Cell Lung
Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments
This is a multicenter, prospective, single-arm clinical study to determine the efficacy and safety of Drug-eluting beads bronchial arterial chemoembolization（DEB-BACE） in stage II-III NSCLC patients who failed, refused or…
- Trial name
- NCT04825925
- Testing
- DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung
Because of the effect in the treatment of NSCLC, the capecitabine and erlotinib may compose to a new regimen for NSCLC. Based on the preclinical observation and the confirmed clinical synergistic anti-tumor activity of combined…
- Trial name
- NCT00816868
- Testing
- erlotinib in combination with capecitabine
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Stage III Non-small-Cell Lung Cancer
Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC
Resistance of hypoxic tumor cells to radiation is a significant reason of failure in the local control of tumors, especially the squamous cell carcinomas.
- Trial name
- NCT01733589
- Testing
- Recombinant human endostatin, Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles, cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Zhejiang Cancer Hospital
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal…
- Trial name
- NCT02438722
- Testing
- Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
- Where
- 638 sites in United States
- Volunteers
- 174 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer, Nonsmall Cell
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.
- Trial name
- NCT06319950
- Testing
- Furmonertinib, Osimertinib
- Volunteers
- 255 people
- Sponsor
- Taizhou Hospital
Non-small Cell Lung Carcinoma
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
This is a multicenter, randomized, open label, phase III study.
- Trial name
- APEX (NCT04762459)
- Testing
- Almonertinib, Pemetrexed, Cisplatin
- Where
- 34 sites in China
- Volunteers
- 606 people
- Sponsor
- Chinese Academy of Medical Sciences
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
1. Goals The primary goal of this phase II trial is to: evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in patients with stage IIIB/IV non-adenocarcinoma, non-small cell lung cancer (NSCLC)…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous, Carcinoma, Large Cell
- Trial name
- NCT01497041
- Testing
- Docetaxel, Oxaliplatin
- Where
- 5 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- Korean South West Oncology Group
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can…
- Conditions
- Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06632327
- Testing
- Surgical Procedure, Cisplatin, Carboplatin
- Where
- 415 sites in United States
- Volunteers
- 37 people
- Sponsor
- Alliance for Clinical Trials in Oncology
NSCLC, Stage I
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm.
- Trial name
- NCT04317534
- Testing
- Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 244 people
- Sponsor
- Greg Durm, MD
Carcinoma, Non-Small-Cell Lung
TAilored Post-Surgical Therapy in Early Stage NSCLC
Our hypothesis is that patients receiving therapy based on their baseline tumor ERCC1 levels and EGFR mutations would attain better disease free survival rates than patients in the control arm receiving noncustomized therapy.
- Trial name
- TASTE (NCT00775385)
- Testing
- Standard Chemotherapy, Customized Treatment
- Where
- 42 sites in France
- Volunteers
- 152 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Non-small Cell Lung Cancer
Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)
This study including two parts，one part is a randomized clinical trial design，another part is a registration study.
- Trial name
- NCT03198117
- Testing
- Huaier Granule
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Lung Cancer
Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293280
- Testing
- lomustine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-small Cell Lung Cancer
Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer
The study is designed to determine whether an accelerated course of hypofractionated radiation therapy with daily image guidance and motion assessment/control will allow more effective treatment of poor performance status…
- Trial name
- NCT01459497
- Testing
- Radiation Therapy, Conventional radiation
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- University of Texas Southwestern Medical Center
Non-small Cell Lung Cancer
Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases
The main objective of this trial is to compare feasibility and efficacy of sequential neoadjuvant chemoradiotherapy with 44Gy concomitant boost to neoadjuvant chemotherapy alone.
- Trial name
- NCT01187290
- Testing
- neoadjuvant chemoradiotherapy
- Volunteers
- 80 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Stage II-III Non-small Cell Lung Cancer
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC
This is a randomized, double-blind, placebo-controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of Toripalimab injection (JS001) combined with platinum-based doublet drug chemotherapy versus…
- Trial name
- NCT04158440
- Testing
- 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab
- Where
- China
- Volunteers
- 501 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.